C hronic inflammatory infiltrates that take on the form of organized lymphoid organs are called tertiary lymphoid organs (TLOs). The inflammatory cytokine interleukin-17 is now found to be the critical participant driving the development of a type of TLO called inducible bronchus-associated lymphoid tissue (iBALT) in an animal model of neonatal pulmonary inflammation. 1 The highly organized architecture of secondary lymphoid organs (SLOs), characterized by distinct B-cell and T-cell areas, is evolved to optimize the efficiency of cellular and humoral immune responses. 2 The organization of SLOs is formed during development as a result of the highly orchestrated interplay between hematopoietic cells, stromal cells and naive lymphoid cells. TLOs arise from chronic inflammation in non-lymphoid tissues and bear morphological resemblance to SLOs. TLOs are composed of discrete Tcell and B-cell areas, follicular dendritic cells, resident dendritic cells (DCs), high endothelial venules and lymphatics. However, unlike lymph nodes, TLOs are not encapsulated, suggesting an intimate interaction with the inflamed tissues. The presence of TLOs is thought to allow antigen presentation at the local mucosal tissue with high efficiency and reduce the possibility of disseminating infection. Many molecules that drive the formation of TLOs, a process known as lymphoid neogenesis, are the same as those involved in the development of conventional lymph nodes. 3 The development of SLOs is initiated by lymphoid tissue inducer (LTi) cells, which express lymphotoxin-a 1 b 2 (LT-a 1 b 2 ). 4 LT-a 1 b 2 stimulates the expression of CXCL13 and CCL21 in stromal cells, which are required for the homing of B and T cells to the SLOs. Subsequent studies also demonstrated that overexpression of lymphoid homeostatic chemokines such as CCL21 or CXCL13 promoted SLO generation. 6, 7 Despite these studies, the initiation of lymphoid neogenesis is poorly understood. Randall and colleagues 1 recently identified IL-17 produced by T cells as being required for the formation of iBALT, a type of TLO that forms in the lungs during chronic inflammation and infection. This study provides exciting novel mechanistic insights into the initiating events and the cell components that participate in iBALT formation.
Randall and colleagues induced chronic pulmonary inflammation and iBALT by repeatedly administering lipopolysaccharide (LPS) to the lungs of neonatal C57BL/6 mice. Because LTi cells are involved in the development of conventional lymph nodes, the authors studied whether LTi cells are also involved in the generation of iBALT, by using RORc-deficient mice and Id2-deficient mice, both of which fail to develop LTi cells. Interestingly, both RORc-deficient mice and Id2-deficient mice developed normal iBALT areas, suggesting that LTi cells are not involved in the generation of iBALT. The authors also confirmed previous findings that DCs are critical for the maintenance of iBALT. 8, 9 Using various knockout mice, they further showed that LT-a and homeostatic chemokines, such as CXCL13, CCL19 and CCL21a, were required for the organization of iBALT. In searching for candidate genes for the induction of iBALT, the authors discovered that, after repeated challenge of the lungs with LPS, more IL23p19 and IL-17A were expressed in neonatal lungs than in adult lungs. They further found that IL-17 influenced the number and size but not the architecture of the iBALT, and they uncovered the source of IL-17 as being CD4
1 ab-and cd-T cells. Using an adoptive transfer system, they established that either ab-or cd-T cells were sufficient to establish B-cell aggregates in their model of lung inflammation. Of all of the ab-T cell subsets, which include Th1, Th2, follicular helper T cells and Th17 cells, Th17 cells were found to be the most potent inducers of iBALT. In addition, they found that IL-17 induced the expression of CXCL13 and CCL19 but not CCL21 in isolated pulmonary fibroblasts and that IL-17 was required for the production of these homeostatic cytokines in the LPS-challenged lung tissues.
This study reveals a novel role of IL-17 in iBALT formation. The proposed function of IL-17 is to directly stimulate the expression of CXCL13 and CCL19 in stromal cells. The exact sequence of events that initiates iBALT formation, however, remains to be carefully examined. Both this study and previously published studies have shown that DCs are required for iBALT formation. Therefore, the initiating events might involve DCs being activated by LPS within the lungs and then migrating to the lung-draining lymph nodes, where they initiate the generation of Th17 cells. This local activation of myeloid cells would be followed by the activation of cd-T cells, which are expected to be the first cells that produce IL17 in LPS-treated lung tissue. The second cells to produce IL-17 would be pre-activated Th17 cells, which have been generated in the lungdraining lymph nodes and subsequently recruited to the lungs.
The findings of this study are consistent with the role of IL-17 in the initiation of chronic inflammation. 10 In addition to homeostatic chemokines, such as CXCL13 and CCL19, IL-17 induces a wide range of inflammatory chemokines, such as CXCL9, CXCL10 and CXCL11. Blockade of IL-17 reduces the number and size of iBALTs but does not affect the architecture of iBALTs. Thus, IL-17 is more important for inducing tissue inflammation than for organizing the structure of iBALTs. Randall and colleagues' data also show that IL-17 is not required for the maintenance of iBALT, despite its crucial function in iBALT formation. From a therapeutic point of view, this implies that IL-17 blockade might not affect established TLOs but might inhibit the generation of new TLOs, which is responsible for the relapse of autoimmune diseases such as multiple sclerosis. In the future, it will be interesting to determine whether other T-cell subsets are involved in TLO maintenance and organization.
